Key result
Canagliflozin treatment for 3 days did not significantly change fasting serum betatrophin levels compared to control in patients with poorly controlled type 2 diabetes.
Why the study?
Does short-term canagliflozin treatment affect circulating betatrophin levels in patients with poorly controlled type 2 diabetes?
RCT (n=30)
Open-label
Central computer system
No
Does short-term canagliflozin treatment affect circulating betatrophin levels in patients with poorly controlled type 2 diabetes?
Short-term treatment with canagliflozin does not significantly alter serum betatrophin levels, though betatrophin correlates positively with HbA1c, fasting plasma glucose, and HDL-C in poorly controlled type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Short-term canagliflozin leaves betatrophin unchanged in T2D; confirms lack of rapid modulation and directs research to other pathways.
BACKGROUND: Betatrophin is a hormone mainly secreted by the liver that influences lipid metabolisms. The main purposes of this study were to investigate the effect of canagliflozin (a sodium glucose transporter 2 inhibitor) on circulating betatrophin levels, and to investigate the correlation of various markers associated with glucose and lipid metabolisms with betatrophin in patients with poorly controlled type 2 diabetes. METHODS: Patients were randomly divided into a control group (n = 15) and a canagliflozin-treated group (n = 15). After hospitalization, the canagliflozin-treated group took 100 mg/day of canagliflozin for 3 days. Blood tests were performed at baseline and after 3 days of treatment. RESULTS: Canagliflozin treatment for 3 days did not significantly change fasting and postprandial serum betatrophin levels. On the other hand, betatrophin levels had a significant positive correlation with hemoglobin A1c, fasting plasma glucose, and high-density lipoprotein cholesterol levels at baseline. CONCLUSIONS: The current study suggests that short-term treatment by canagliflozin does not influence circulating betatrophin levels, and that betatrophin is positively associated with markers of glycemic control and high-density lipoprotein cholesterol in patients with poorly controlled type 2 diabetes.
No takes yet. Share an insight, caveat, or question.
Takebayashi et al. (2017) conducted an RCT in Poorly controlled type 2 diabetes (n=30). Canagliflozin vs. Control was evaluated on Fasting serum betatrophin levels (ng/mL) (MD 0.14, 95% CI -0.01 to 0.29, p=0.0688). Canagliflozin treatment for 3 days did not significantly change fasting serum betatrophin levels compared to control in patients with poorly controlled type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: